These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38899713)

  • 21. [A critical appraisal of the European guidelines on diabetes, pre-diabetes and cardiovascular diseases].
    Miccoli R
    G Ital Cardiol (Rome); 2014 Jun; 15(6):350-4. PubMed ID: 25072420
    [No Abstract]   [Full Text] [Related]  

  • 22. Is glucose control important for prevention of cardiovascular disease in diabetes?
    Mannucci E; Dicembrini I; Lauria A; Pozzilli P
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S259-63. PubMed ID: 23882055
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.
    Purnell JQ; Braffett BH; Zinman B; Gubitosi-Klug RA; Sivitz W; Bantle JP; Ziegler G; Cleary PA; Brunzell JD;
    Diabetes Care; 2017 Dec; 40(12):1756-1762. PubMed ID: 29138273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?
    Snaith JR; Greenfield JR
    Med J Aust; 2022 Aug; 217(3):126-128. PubMed ID: 35772726
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.
    Pop-Busui R; Braffett BH; Zinman B; Martin C; White NH; Herman WH; Genuth S; Gubitosi-Klug R;
    Diabetes Care; 2017 Jan; 40(1):94-100. PubMed ID: 27803120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-High-Density Lipoprotein Cholesterol in Children with Diabetes: Proposed Treatment Recommendations Based on Glycemic Control, Body Mass Index, Age, Sex, and Generally Accepted Cut Points.
    Schwab KO; Doerfer J; Hungele A; Scheuing N; Krebs A; Dost A; Rohrer TR; Hofer S; Holl RW
    J Pediatr; 2015 Dec; 167(6):1436-9. PubMed ID: 26427965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet glycoprotein IIb/IIIa receptor inhibitors: is their future as bright as their past?
    Leesar MA
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):907-8. PubMed ID: 18498141
    [No Abstract]   [Full Text] [Related]  

  • 28. [Prevention of diabetes mellitus type 1].
    Scherbaum WA; Hauner H
    Dtsch Med Wochenschr; 2005 Jan; 130(4):141-2. PubMed ID: 15662579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs That Improve Cardiovascular Prognosis in Diabetes and Are Not Yet Used by Cardiologists.
    Castro A; Marzal D
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):999-1000. PubMed ID: 30219492
    [No Abstract]   [Full Text] [Related]  

  • 30. Emerging Targets for Cardiovascular Disease Prevention in Diabetes.
    Stitziel NO; Kanter JE; Bornfeldt KE
    Trends Mol Med; 2020 Aug; 26(8):744-757. PubMed ID: 32423639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo approaches to prevention and cure of T1D.
    Gottlieb PA
    Curr Diab Rep; 2005 Apr; 5(2):77-8. PubMed ID: 15794907
    [No Abstract]   [Full Text] [Related]  

  • 32. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of intensive glycaemic control on cardiovascular outcomes.
    Hill D; Fisher M
    Diabetes Obes Metab; 2010 Aug; 12(8):641-7. PubMed ID: 20590740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New drugs for type 2 diabetes: expanding cardiovascular protection beyond type 2 diabetes?].
    Mannucci E
    G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):3S. PubMed ID: 23258122
    [No Abstract]   [Full Text] [Related]  

  • 35. [Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Results of the DCCT/EDIC study].
    Liakishev AA
    Kardiologiia; 2006; 46(3):73. PubMed ID: 16710261
    [No Abstract]   [Full Text] [Related]  

  • 36. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 37. Insulin therapy in type 1 diabetes.
    Stephens E
    Med Clin North Am; 2015 Jan; 99(1):145-56. PubMed ID: 25456648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
    Bethel MA; Califf RM
    Am J Cardiol; 2007 Mar; 99(5):726-31. PubMed ID: 17317381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial.
    Anderson J; Peña AS; Sullivan T; Gent R; D'Arcy B; Olds T; Coppin B; Couper J
    BMC Pediatr; 2013 Jul; 13():108. PubMed ID: 23865839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes.
    Doggen K; Nobels F; Scheen AJ; Van Crombrugge P; Van Casteren V; Mathieu C
    J Diabetes Complications; 2013; 27(4):370-5. PubMed ID: 23537603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.